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Abstract 
Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints 
and increasingly recognised by regulators, clinicians and patients as valuable tools to collect patient-
centred data. PROs provide unique information on the impact of a medical condition and its treatment 
from the patient’s perspective, therefore PROs can be included in clinical trials to ensure the impact of a 
trial intervention is comprehensively assessed. This manuscript first discusses examples of how PRO 
endpoints have added value to clinical trial interpretation. The second half of this manuscript describes 
problems with current practices in designing, implementing and reporting PRO studies, and how these 
problems may be addressed by complying with guidance for protocol development, selecting 
appropriate PRO measures to match clinically-motivated PRO hypotheses, minimising the rates of 
avoidable missing PRO data, analysing and interpreting PRO data, and transparently reporting PRO 
findings.  
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Introduction  
Patient-reported outcomes (PROs) are defined as  “any report of the status of a patient’s health 
condition that comes directly from the patient, without interpretation of the patient’s response by a 
clinician or anyone else” (Food and Drug Administration (FDA), 2009, p6).1 PRO is an umbrella term 
which may refer to patient-reported: 1) disease symptoms or treatment side-effects, such as pain, 
fatigue, or anxiety; 2) functional outcomes such as physical, sexual, social, role, emotional, or cognitive 
functioning; or 3) multi-dimensional constructs such as health-related quality of life (HRQOL) or health 
utility. HRQOL is defined as “the subjective assessment of the impact of disease and treatment across 
the physical, psychological, social and somatic domains of functioning and well-being” (Revicki et al., 
2000, p888).2 In this manuscript, we focus on PROs as clinical trial endpoints and differentiate PROs from 
other types of patient-reported measures, such as patient-reported experiences, or patient-reported 
behaviours, which may also be included as clinical trial endpoints.  
PROs are assessed in trials using questionnaires, often referred to as “PRO measures”. Validated PRO 
measures are used in clinical trials, as opposed to asking participants open-ended questions about their 
outcomes, to ensure that the questions, response options and the general approach to assessment are 
standardized for all participants. This enables the research team to attribute any differences between 
patient responses to real differences in perceptions of their outcomes, as opposed to methodological 
differences or biases. PRO measures are typically developed with input from clinicians, patients, and 
psychometric experts to ensure that the PRO measure assesses clinically relevant issues that are 
meaningful to patients in a robust manner. 
PROs provide unique information on the impact of a medical condition and its treatment from the 
patient’s perspective,3,4 therefore PROs can be included as trial endpoints to ensure the impact of a trial 
intervention is comprehensively assessed.  In palliative care or rehabilitation trials, PROs may be the 
primary endpoint of interest. In other trials they may be included as secondary endpoints to support and 
help interpret the primary endpoint. In some contexts, PROs may be included as exploratory or tertiary 
endpoints, with the intention of generating hypotheses for testing in future studies. Including PROs in a 
clinical trial requires careful thought regarding the specific research questions to be addressed and the 
needs of all stakeholders including patients, clinicians, trial sponsors and regulatory authorities.  
Importance of including PROs in clinical trials 
Increased use and recognition of PROs  
The use of PROs in clinical trials has increased over time. Consecutive reviews of ClinicalTrials.gov in 
2004-20075 and 2007-20136 determined that use of PRO endpoints had increased  from 14% to 27% of 
trials over that period. A more recent review of the Australian New Zealand Clinical Trials Registry  
determined that 45% of trials registered 2005-March 2017 included PROs and there was a strong 
increase in the proportion of trials with PROs registered over time (r=0.74, p=0.009).7 Similarly, between 
2000-2015, the Center for Devices and Radiological Health reported an increase of over 500% in pre-
market submissions including PRO measures.8 
Increases in the use of PROs in clinical trials may be attributable to top-down encouragement from 
professional societies and regulatory bodies.9  In oncology, for example, the American Society of Clinical 
Oncology (ASCO),10 and European Society for Medical Oncology (ESMO)11 have proposed standardized 
approaches to evaluate clinical trial results by using scores to evaluate the Magnitude of Clinical Benefit 
(ESMO MCB) or the Net Health Benefit (ASCO), which include survival endpoints in addition to toxicity 
and HRQOL.10,11 The ESMO MCB scores based on survival outcomes are upgraded if there is evidence to 
indicate improved, or delayed deterioration in, HRQOL using validated PRO measures, or a substantial 
reduction in adverse events. The ESMO and ASCO recommendations are clearly important in evaluating 
new therapies and highlight the importance of including PRO endpoints in clinical trials.  
Furthermore, the Australian government supports a Quality of Life Office to work with the 13 National 
Cancer Clinical Trials Groups  to include PRO endpoints in investigator-initiated oncology trials.12 The 
European Medicines Agency released guidance in 2016 on the use of PROs in the evaluation of anti-
cancer medicinal products.13 PROs have also been highlighted by professional oncology societies as 
important endpoints in specific oncology trial contexts, for example, in ovarian cancer clinical trials.14-17  
Beyond oncology, the FDA released guidance in 2009 on the evaluation of PRO measures used to 
support medical product labelling claims. This guidance aimed to improve the efficiency and 
transparency of discussions between sponsors and the FDA during the drug development process, to 
streamline the FDA’s review of PRO measures and associated clinical trial data, and to improve methods 
for considering patients’ perspectives in the medical product review process.1 The Organization for 
Economic Co-operation and Development recently highlighted the importance of collecting PROs to 
enable a more complete understanding of health system performance.4 In 2017 the Medicare Evidence 
Development and Coverage Advisory Committee, USA, determined that quality of life measures were of 
particular interest and should be included as health outcomes in future heart failure studies.8,18 
What value do PROs add to clinical trials?  
Au and colleagues reviewed Phase III oncology cancer trials led by the National Cancer Institute of 
Canada Clinical Trials Group and classified the benefits of including a PRO as a trial endpoint into three 
categories. Firstly, PROs may assist clinicians and future patients to select the best treatment by 
providing a clearer picture of the costs and benefits of treatment.3 Secondly, PRO data can enrich our 
understanding of the patient’s experience with unique information that could not be gained from 
biomedical outcomes alone, as certain domains are difficult to observe (e.g. pain, fatigue) and outcomes 
such as the degree of symptom bother are subjective and best collected through patient-report.3 
Thirdly, PROs can help to improve future clinical trial methods.3 In contexts where certain PROs have 
confirmed prognostic significance, PROs can be used to stratify participants. Furthermore, careful 
examination of PRO assessment compliance  can illuminate areas where methodological improvement is 
needed.3 
Other applications of PRO data include informing regulatory decisions, cost-effectiveness analyses, and 
informing clinical guidelines and health policy. Patient advocacy groups promote use of PROs as they 
enable patients to communicate their experience, assess whether their experience aligns with their 
expectations of treatment, and highlight areas of unmet need or care in need improvement.19 For these 
reasons, patient advocates are vocal about the importance of including PROs.19,20 In an era where 
consumer input into clinical trial protocols is highly valued and encouraged, advocacy for PRO endpoints 
may result in increased implementation of PRO endpoints in clinical trials.  
 
Examples of how PROs have contributed to interpretation of clinical trial results 
Investigators should determine primary and secondary trial endpoints a priori according to what is 
appropriate for interpretation of the individual clinical trial. As a secondary endpoint, PRO data can add 
information to assist the interpretation of primary trial endpoints. In other clinical contexts, it may be 
appropriate for the PRO to be the primary trial endpoint. There is no “one-size” approach to interpreting 
PRO data; all clinical trial data including PROs should be interpreted in context. There are numerous 
examples where PRO data, interpreted in conjunction with other trial outcomes, have been 
fundamental to understanding patients’ perceptions of the risks and benefits of treatment and have 
impacted the interpretation of the trial results.  
A clinical trial comparing prednisone with or without mitoxantrone in men with metastatic prostate 
cancer found that although there was no difference in overall survival (p=.27), or serum prostate-specific 
antigen levels (p=.11) between the 2 arms,21 the patients receiving mitoxantrone experienced significant 
improvement in PROs. The primary outcome was palliation of pain (response defined as a 2-point 
reduction in the 6-point pain intensity scale of the McGill-Melzack Pain Questionnaire, or complete loss 
of pain if the patient initially scored >1, maintained on two consecutive, three-weekly evaluations, 
without an increase in analgesic score). Response rates were 29% (95% confidence interval (CI): 19%, 
40%) in the mitoxantrone +  prednisone group and 12% (95% CI: 6%, 22%) in the prednisone alone 
group, (p = .01). Further, pain (severity, impact, relief), fatigue, mood, aspects of functioning, global QOL 
and other PROs improved with mitoxantrone + prednisone from baseline (p<.01).21,22 The PRO endpoints 
led to regulatory approval for mitoxantrone for this indication and wide implementation in the clinic. 
In a trial of Ruxolitinib compared to placebo for the treatment of intermediate or high-risk myelofibrosis, 
Ruxolitinib was found to improve fatigue, as assessed by the Patient Reported Outcomes Measurement 
Information System (PROMIS) Fatigue 7-item short form.23 PROMIS Fatigue is included on the Ruxolitinib 
label accordingly, along with PRO data from a previous study which demonstrated that Ruxolitinib was 
associated with a greater proportion of patients experiencing a reduction of 50% or more in patient-
reported myelofibrosis symptoms (abdominal discomfort, pain under left ribs, early satiety, night 
sweats, itching, bone/muscle pain, and inactivity), as well as significant improvement (p<0.001) in these 
symptoms until 20 weeks, and until 24 weeks for abdominal discomfort, early satiety, and itching. 
Conversely, the placebo arm experienced a steady decline across all myelofibrosis symptoms over the 24 
weeks.24 
Gnanasakthy and colleagues have published a series of papers detailing FDA labels that include PRO data 
that support regulatory approvals.25-27 Between 2006 and 2010, 28 of 116 (24%) products approved by 
the FDA were granted PRO claims. Of these products, 71% included a PRO as the primary trial endpoint, 
and pain related endpoints were most common (38%).27 Between 2011 and 2015, 30 of the 182 (17%) 
new drugs approved by the FDA received PRO labeling. Again, many of these were trials with primary 
PRO endpoints (77%).26 Between 2010 and 2014, 40 drugs were approved by the FDA Office of 
Hematology and Oncology Products, of which three (8%) were granted PRO labeling.25 A further 13 
oncology trials included PROs on the Drug Approval Package (“a summary of clinical study reports and 
related documents written by the FDA staff after data from pivotal studies submitted by the study 
sponsors has been reviewed”) (Gnanasakthy et al., 2016,25p2), but did not receive PRO labeling due to 
various reasons, including: inappropriate choice of PRO measure, high rates of missing PRO data, and 
poor reporting of PROs.25  
Strategies for future optimization 
In this section we summarise the current challenges with PRO use in trials and present solutions and 
guidance to address these issues.  
Protocol development 
Issues with current practice  
There is good evidence that trial protocols are often incomplete with regard to PRO endpoints. A review 
of 75 trial protocols (all clinical areas) with PRO endpoints submitted to the United Kingdom (UK) 
National Institute for Health Research (NIHR) Health Technology Assessment program in 2012-13 
determined that only 8% of the 75 trials studied described a rationale for PRO assessment, 60% 
addressed PRO-specific quality assurance issues, and only 8% offered PRO data collection instructions.28 
Overall, protocols addressed a mean of 33% of recommended PRO items.28 
A second review examined the PRO content of 26 phase III international, ovarian cancer trial protocols 
published 2000-2016 against a list of PRO-specific items that would eventually inform the Standard 
Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension.29,30 Of the 26 trials, 
one had a co-primary PRO endpoint, and 25 had secondary PRO endpoints). This review demonstrated 
that overall coverage of recommended PRO items ranged from 8-66% (mean coverage 28%). Only two 
protocols addressed more than half of the recommended and applicable items. Basic aspects of PRO 
research design, including the primary/secondary status of the PRO endpoints and assessment 
schedules, were addressed in the majority of ovarian cancer trial protocols; 92% and 96% respectively. 
However, key guidance about PRO administration and quality assurance was often incomplete or 
omitted. For example only 23% of these trial protocols specified time windows for each scheduled PRO 
assessment.30 Assessment windows are particularly important in trials of chemotherapy because of its 
fluctuating and transient side effects. If the PRO assessment seeks to capture the acute impact of 
chemotherapy on HRQOL, the time windows specified in the protocol should capture the days where 
the effects of chemotherapy toxicity would be felt. Without time windows, trial staff may not realise the 
time-sensitive nature of the scheduled assessment, which may lead to uninformative PRO data or biased 
interpretation if the time window is missed. Further trial staff who do not administer the PRO measure 
on the targeted date may not realise they can validly continue to pursue that PRO assessment for a few 
more days, leading to that PRO assessment being missed.  
Additionally, only 31% of protocols specified a PRO-specific objective and only 19% included a PRO 
hypothesis.30 This is poor practice because it makes it difficult to assess whether the PRO study was 
designed around a clinically motivated and relevant research question, and hence whether the choice of 
PRO measures and assessment time points was appropriate and would provide meaningful data for 
subsequent interpretation of the trial findings alongside other clinical endpoints.   
These examples illustrate the importance of providing clear and comprehensive PRO study content in 
trial protocols, as this ensures high-quality data are collected using consistent data collection methods 
to inform any clinical recommendations resulting from the trial. 
A third study is underway, which will review the PRO content of cancer trials (all cancers) submitted to 
the UK NIHR Portfolio,31 however at the time of this review, the results had not been published. 
PRO-specific protocol guidance available 
The SPIRIT statement was published in 201332,33 and provides an evidence-based list of items 
recommended for inclusion in trial protocols. Until recently, no such consensus-based guidance for PROs 
existed. In 2018 the SPIRIT-PRO guidance was released.29 SPIRIT-PRO is the product of years of 
methodological research and an international, expert consensus process that aimed to identify the 
essential items to include in PRO sections of clinical trial protocols. It should be used in conjunction with 
the SPIRIT 2013 Statement 32,33 when developing a research protocol for a trial with a primary or 
important secondary PRO endpoint. SPIRIT-PRO contains 16 items, 11 of which are new, PRO-specific 
“extensions” to the core SPIRIT 2013 checklist, and five PRO-specific “elaborations” on existing SPIRIT 
2013 items. The SPIRIT-PRO Extension items address: the PRO study rationale, objectives, eligibility 
criteria, PRO domains used to evaluate the intervention, assessment time points, selection of PRO 
measures, measurement properties of these PRO measures, the PRO data collection plan, translation of 
PRO measures to other languages, proxy completion, strategies to minimize missing PRO data, and 
whether PRO data will be monitored during the active trial phase to inform the clinical care of 
participants.29 The full checklist is available in the SPIRIT-PRO publication29 and on the EQUATOR 
(Enhancing the QUAlity and Transparency Of health Research) Network website.34  
Appropriate choice of PROs and PRO measures. 
Issues with current practice  
The suitability of PRO measures  to address pre-specified hypotheses was evaluated in 66 head and neck 
cancer and thyroid (HNT) cancer clinical trials published 2004-2015; (22 with primary PRO endpoints, 44 
with secondary PRO endpoints).35 This study found that only eight of the 66 studies (12%) reported a 
PRO hypothesis, and all of these chose an appropriate PRO measure, which assessed and produced 
scores for the constructs specified in their hypotheses. While the sample size was small (n=8), this result 
suggested that explicitly specifying a PRO hypothesis a priori engaged investigators to carefully consider 
the constructs of particular relevance to their clinical population and selection of appropriate PRO 
measures. PRO measures that are more suited to the specific research question cannot yield the 
required information, resulting in a waste of resources and time in collecting PRO data. It is concerning 
that 58 (88%) of the HNT randomized controlled trials (RCTs) failed to report any PRO hypotheses, 
precluding assessment of the suitability of their chosen PRO measures.35 
Furthermore, five (8%) of the 66 HNT RCT publications did not name the PRO measure used. Many more 
RCTs modified validated PRO measures without specifying the nature of the modifications.35 
Modifications may have involved rewording, removing, or adding items, or altering scoring procedures, 
and may have compromised the psychometric properties of the PRO measures. None of these RCTs 
assessed the impact of these modifications on the measure’s psychometric integrity and performance. A 
follow-on issue is that the publication of RCTs using modified questionnaires may set a precedent for 
future RCTs to use the modified version rather than the validated version, thereby potentially 
perpetuating the problem of use of poor quality PRO measures. 
As noted earlier, the FDA has declined to provide PRO labeling on the basis that clinical trials have not 
selected an appropriate PRO measure, or that the measure had not been appropriately developed and 
validated.25 This suggests the problem occurs even among well-funded and well-resourced trials 
presented to the FDA. 
Guidance available for selection of PRO measures 
Clinicians, patients, researchers and other relevant stakeholders should be involved in discussions about 
important, clinically-relevant PROs and corresponding appropriate and valid PRO measures. Kluetz and 
colleagues eloquently state: “The goal [of PRO measure selection] should be to achieve a comprehensive 
evaluation of the patient experience most affected by the therapy, while maximizing the relevance of 
individual questions and minimizing overall burden and duplication.” p1557.36 
Snyder and colleagues describe how to develop a measurement strategy for prospective labeling 
claims.37 This involves identifying relevant PRO domains, developing a conceptual framework around 
these domains, identifying approaches to measure these domains and designing a measurement 
strategy based on this information. Snyder acknowledges that existing scales may not fit the study’s 
purpose and advocates that modifications to PRO measures should be subject to reliability and validity 
tests prior to implementation.37  
Luckett and King describe six guiding principles towards selecting a PRO measure in cancer clinical 
research, however the principles apply more broadly. These principles state that researchers should:  
1) consider PRO measures early in the study’s design,  
2) select a primary PRO that is proximal to the disease or treatment (i.e. symptoms or direct 
treatment side-effects as opposed to down-stream impact on HRQOL),  
3) ensure that the PRO items (individual questions) are appropriate to the study and consider 
how the items combine into summary scales,  
4) appraise evidence regarding the PRO measure’s reliability and validity,  
5) consider practicalities such as respondent burden, mode of administration, and the need for 
validated language translations, and  
6) take a minimalist approach to ad hoc items, that is, avoid adding to or modifying existing PRO 
measures.38  
As these guidelines demonstrate, trial investigators are increasingly being encouraged to measure 
proximal PROs, such as symptoms, in preference to measuring more distal or multi-dimensional 
constructs such as HRQOL, as primary PRO endpoints. This is because more distal domains are more 
likely to be influenced by factors beyond the trial interventions, such as social context and other life 
events. The FDA advises against HRQOL alone as an outcome in the era of novel therapies and 
recommends a focused and flexible approach to PRO measure selection. The PROMIS suite and PRO-
CTCAE (Patient reported outcome Common Terminology Criteria for Adverse Events) have been 
identified as being well-suited to this measurement approach.36 
PRO administration  
Trial staff experiences 
A study conducted in UK interviewed trial staff about their experience with PRO studies, across a range 
of health conditions, found trial team members felt they lacked guidance and training for PRO studies. A 
problematic issue related to how to deal with concerning PRO data, for example very high anxiety scores 
or when participants wrote comments about their PRO scores on questionnaire sheets, as this was 
infrequently addressed in trial protocols and training.39 
An Australian study of 20 cancer clinical trial coordinators revealed that PRO administration procedures 
were often unclear regarding: participants who could not complete questionnaires in English, handling 
participants’ family members who attempted to complete PRO measures, whether to approach 
participants who appeared unwell or distressed, how to handle concerning PRO responses, and being 
flexible to participants’ needs whilst also adhering to protocol procedures.40 Coordinators were 
uncertain how to respond to these challenges, particularly if they perceived a discord between their 
duty of care and their trial coordinator role, or if they had received conflicting instructions previously. 
For example, whether to act on concerning PRO score if instructed not to check completed 
questionnaires.40 
Poor PRO administration practices were common. Trial participants were often not fully informed about 
the nature of their research participation, for example, if PROs were not addressed at the trial consent 
stage, or if the purpose of PRO assessments was not discussed at all. The timing and mode of PRO 
administration often departed from the protocol. Some sites failed to train back-up personnel for when 
primary trial coordinators were absent from work, leading to missing PRO data during the primary 
coordinator’s absence.40 
Furthermore, PRO training was a key concern. Only two of the 20 coordinators interviewed received 
PRO-specific training, and two others received no PRO training whatsoever.40 PRO training was more 
frequently provided by colleagues or briefly addressed at trial start-up meetings. As a result, trial 
coordinators often received inconsistent guidance regarding PRO administration, leading to confusion 
and use of inconsistent methods. Despite this, 55% of trial coordinators felt they did not need further 
PRO administration training40 in contrast to the UK study,39 which may present a barrier to their future 
attendance of PRO training courses. The general lack of PRO training reported by many of the 
coordinators interviewed raises concerns about the extent to which trial sponsors are complying with 
the good clinical practice guideline that trial staff must be adequately trained.41 
Modes of administration 
There is extensive literature regarding different modes of questionnaire administration, comparing both 
the methods (such as paper-based, electronic (computer, smartphone or tablet), telephone interview, 
etc.) and setting (home, clinic) of administration. In our experience, paper-based and electronic modes 
of administration are most commonly used methods. Pros and cons of each method are presented as 
Table 1.   
A recent meta-analysis found no difference in patient responses (bias) between electronic and paper-
based methods when the patient self-completed questionnaires. The authors concluded that self-
completed questionnaires originally developed for paper-based administration could be safely be 
administered by electronic modes, or both modes could be used in any one study. However, when self-
completed questionnaire data (paper or electronic administration) was compared to administered 
modes (i.e. questionnaire administered by a researcher over the phone or face-to-face) there was a 
slight difference in responses according to the setting of administration (at home vs in clinic). Therefore 
the authors recommended that if using self-complete and administered modes, the setting of 
administration should be kept consistent.42 Future meta-analyses are needed to determine whether 
mode of administration impacts questionnaire return rate or participant retention, and whether the 
questionnaire return method (i.e. returning to a coordinating centre rather than to the recruitment site) 
impacts responses or return rate. 
Burden associated with PRO assessment 
It is important that investigators consider the extent to which PRO assessment may become 
burdensome to participants, trial staff and statisticians. Unnecessary burden must be minimised. PRO 
assessment may become burdensome in a number of ways, as detailed in Table 2: 
PRO administration guidance 
Trial staff should receive clear PRO administration instructions in order for PROs to be administered 
consistently. Impressing the critical importance of PROs to the interpretation of trial results to trial 
coordinators and clinicians is required before the trial opens. Consensus guidelines for PRO 
administration are lacking, although many good examples of guidance developed by individual groups 
exist. For example, the European Organisation for the Research and Treatment of Cancer (EORTC) 
guidelines43 the South West Oncology Group (SWOG) Training Module, presented by Dr Lisa Hansen 
(available for SWOG trials) and the QOL Office Checklist of instructions for the administration of Patient 
Reported Outcome Measures.44 Future research should develop consensus-based PRO administration 
guidance and test the efficacy of accompanying training interventions. 
Experienced clinical trials groups such as SWOG45 and the Epidemiology of Diabetes Interventions and 
Complications group46 have seen benefits including increased PRO compliance, improved work 
satisfaction, and participant retention, as a result of involving trial coordinators or researcher nurses 
more actively in the research process and investing more resources in their professional development. 
These groups also engage experienced coordinators in training new coordinators. A more formal 
approach to peer-training may be a feasible and acceptable approach to future trial coordinator training 
efforts for PRO administration.   
Missing PRO data 
Issues with current practice 
It is important to minimize the rates of missing data in clinical trials. High rates of missing PRO data can 
reduce study power,47 inflate risk of Type 2 error,48 bias interpretation47 and potentially undermine 
randomisation.49 Fielding and colleagues determined that 18% of RCTs published in the four highest-
impact medical journals between 2005 and 2006 had missing PRO data rates exceeding 20%, and a 
further 20% of trials failed to clearly report rates of missing PRO data.50 In many cases, the methods 
used to address missing PRO data in these trials were unclear or unsatisfactory.50 In an update of this 
review (2013-2014), approximately 8% of RCTs published in high-impact journals used complete case 
analysis for PROs51 despite the inappropriateness of this approach in many contexts.52,53 Furthermore, 
the rate of missing PRO data was unclear in 35% of studies, 10% of trials had more than 20% missing 
PRO data, and only 13% indicated the missing data mechanism51 (system for classifying missing data 
according to their cause).48,54,55 It is important to deduce and report the likely missing data mechanism 
because this allows researchers to handle missing data appropriately, to select appropriate analysis 
methods, and to interpret results with caution. Often the missing data mechanism has a stronger impact 
on the results than does the proportion of missing data 52,56. For example, if analysis methods assume 
that missing data are not related to the patients’ illness (e.g. “complete case” analysis methods), when 
this was not truly the case, the results may falsely indicate that the outcome is favourable (bias). It is 
impossible to determine the true missing data mechanism, but information about the clinical status of 
the patient or the reasons for missing data, particularly whether these reasons are related to the 
patient’s worsening illness or not, can assist researchers in deducing the underlying mechanism52.  
 
A review of the rates of missing PRO data in 36 ovarian cancer trials found similar problems to those 
noted above.57 Many of these trials included patients with advanced/recurrent ovarian cancer, which 
may be associated with early progression and high mortality. Hence, a degree of missing data or trial 
drop out is expected to be related to worsening health status of the trial participants. It is concerning 
that the reasons for missing PRO data were indiscernible for 72% of the publications studied. In the 10 
RCTs (28%) that transparently reported PRO compliance rates (i.e. those that differentiated between 
avoidable and informative sources of missing data), the rates of avoidable missing PRO data were at 
times very high. The worst compliance rate was 59% (i.e. 41% of trial participants had avoidable missing 
data (not illness-related). This suggested that trials did not sufficiently implement strategies to minimise 
avoidable missing PRO data. Analysis of the corresponding trial protocols for 26 of these 36 RCTs (72%) 
determined that trials that had less complete PRO protocol sections (i.e. addressed the lowest number 
of recommended PRO protocol checklist items) had the highest rates of avoidable missing PRO data. 
This suggests a plausible link between the quality of PRO content of the protocol and the quality of PRO 
data collected, highlighting the importance of comprehensively addressing PROs in the trial protocol.57 
Palmer and colleagues developed a classification framework for factors associated with missing PRO 
data. This framework includes five categories: instrument (questionnaire content, length, language, 
etc.), participant (disease stage, physical impairment, refusal, etc.), centre (infrastructure, location, etc.), 
staff (interpersonal skills, knowledge, motivation, etc.), and study-related factors (frequency and timing 
of assessment, mode of administration, type of treatment etc.).58 Due to a majority of studies failing to 
report the reasons of missing PRO data, it is impossible to reliably estimate the rates of missing data 
attributed to these different categories. Research conducted in the late 1990s suggested that logistic 
and administrative errors was a larger problem with respect to missing PRO data than patient-related 
and design factors59.   
Guidance available on missing PRO data 
Although methods exist to address problems with missing data statistically,60,61 it is better practice to 
prevent avoidable types of missing PRO data, such as failure to provide the questionnaires to patients, 
whenever  possible, and to also clearly report the rates, reasons and handling of missing PRO data in 
publications.55 
A large systematic review of strategies for minimizing the problem of missing PRO data revealed how 
the whole trial team can actively reduce problems of missing PRO data across all research stages.55 
During study design, strategies include: specifying a clinically informative and feasible PRO assessment 
schedule with defined acceptable time windows and stopping rules, collecting auxiliary data clinically 
relevant variables that are correlated with PRO data and recorded at the same time points) to facilitate 
unbiased interpretation of PRO data in the presence of missing data and inform statistical imputation of 
missing PRO data, specifying clear eligibility criteria for the PRO study including literacy and language 
requirements and the need for a valid baseline PRO assessment; ensuring the PRO study is feasible and 
adequately resourced, ensuring the mode of questionnaire administration is feasible and acceptable, 
minimising participant burden, selecting a clinically relevant and validated PRO measure, incorporating 
PROs into all relevant trial documents, involving patient partners and site staff in the design of PRO 
studies, ensuring the trial team is committed to the PRO study, developing quality assurance 
procedures,  ensuring the PRO sample size is representative and sufficient for planned analyses, and 
involving a multidisciplinary team  into PRO study design.55 
Implementation strategies include: developing standardised PRO administration procedures, educating 
and engaging participants, maintaining patient records, appointing a site coordinator responsible for 
PRO assessment at each recruiting site, ensuring the trial team remains engaged and committed to the 
PRO study, and training trial staff.55 
Reporting strategies for addressing the problem of missing PRO data include: clearly reporting study 
and PRO analysis methods, describing the sample including baseline PRO scores, defining and providing 
PRO compliance rates, comparing participants with and without missing PRO data, providing reasons for 
missing data and discussing the impact of missing data on generalisability.55 
Analysis 
Issues with analysis of PRO studies 
A major challenge for the analysis of PRO data is that there are many different analytic approaches 
available, which has caused confusion for researchers, statisticians, clinicians, and others about the most 
appropriate methods and how results should be interpreted. The methodology to be used should be 
determined a priori and included in the protocol with more detailed elaboration of analysis methods 
provided in the statistical analysis plan. 
PRO Analysis Guidance 
The ongoing ‘Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life 
Endpoints Data’ (SISAQOL)62 initiative is developing recommendations for standardised analysis and 
interpretation of PROs in cancer clinical trials, based on international and multi-disciplinary consensus, 
which should become available within the next few years. This initiative acknowledges the challenges in 
using analysis methods that are: suited to the PRO research question, statistically correct, handle 
missing data appropriately, transparent to clinicians, and comparable with results of other trials in 
systematic reviews.62 
 
Reporting 
Issues with reporting of PRO studies 
Readers must be able to appraise the design, analysis and interpretation of a PRO study from its 
publication, therefore transparent reporting is essential. Numerous studies in recent years have 
scrutinized the reporting of PROs in clinical trials, using various checklists of recommended reporting 
items,35,57,63-69 as summarized in Table 3. Table 3 shows variation across the various RCT cohorts studied 
as to how comprehensively studies were reported, overall and at the item level. Items that were 
consistently reported poorly included: PRO hypotheses with PRO domains, approaches to handling 
missing PRO data, and discussions of limitations of the PRO study. In contrast, evidence of the PRO 
measure’s validity was typically provided. 
Failure to report PRO endpoints is also an area of concern. Schandelmaier and colleagues found that 
only 20% of 173 oncology RCTs with a PRO endpoint listed in the protocol subsequently reported PRO 
findings.70 The authors suggested that trial discontinuation was significantly associated with both failure 
to report any PRO data and failure to report PROs as specified in the protocol.70 Schandelmaier’s study 
was based on RCTs approved by six ethics committees from three countries, and results may therefore 
not represent the rate of PRO reporting internationally.70 However, the issue of non-reporting of PROs is 
emerging and requires attention, as it is unethical to waste the funding, resources, and patients’ efforts 
expended in PRO data collection.71 
PRO reporting guidance 
The International Society for Quality of Life Research (ISOQOL) published comprehensive reporting 
standards in 2013,72 consisting of 29 items, 11 of which are only relevant to RCTs with primary PRO 
endpoints and 18 are relevant to trials with either primary or secondary PRO endpoints. This work 
informed the development of a CONSORT-PRO Extension(Consolidated Standards of Reporting Trials), 
which can be considered the minimum reporting items for PRO endpoints (primary or key secondary) in 
RCTs73. CONSORT-PRO consists of 14 items, five of which were newly-developed PRO-specific reporting 
recommendations, (e.g. the PRO should be identified in the abstract as primary or secondary outcome, 
provide evidence of PRO measure’s validity, and report statistical approaches for dealing with missing 
PRO data). The remaining nine CONSORT-PRO items are elaborated from the CONSORT-201074 
statement to specifically address PROs. 
Table 3 shows that RCTs published after release of the CONSORT-PRO73 generally had higher rates of 
reporting on most criteria, particularly those RCTs which cited CONSORT-PRO.69 This suggests a 
preliminary benefit of CONSORT-PRO in improving the standard of reporting, however, given that some 
RCTs that used CONSORT-PRO had incomplete reporting, additional knowledge transfer efforts are 
needed.69 It is encouraging to note that a number of high-ranking journals now request evidence of 
compliance with the CONSORT-PRO checklist when reporting PRO endpoints.  
 
Guidance across PRO research stages 
We encourage readers to access these key resources, which provide excellent guidance across research 
stages:  
o Fairclough DL. Design and analysis of quality of life studies in clinical trials. 2nd ed. 
Florida: Taylor and Francis Group; 2010. 
o Fayers P, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of 
Patient-reported Outcomes. 2nd ed. Chichester, UK: John Wiley & Sons; 2007. 
o The Centre for Patient Reported Outcomes Research (CPROR) PROlearn resources:  
www.birmingham.ac.uk/prolearn  
Conclusion 
Ongoing methodological research is important for determining what constitutes best practice in PRO 
research, and adhering to those standards. High-quality clinical trials inform clinical practice and policy. 
Researchers and clinical trial investigators therefore must implement evidence-based strategies to 
promote high-quality PRO data collection, analysis, and reporting of PRO evidence. This process must 
begin with improved, PRO-specific education for trial team members about the core principles and 
methods for PRO research, with particular focus on strategies to minimise the frequency and effects of 
missing data. PRO aspects of trial protocols should be developed in accordance with the SPIRIT-PRO 
guidance29. Multi-disciplinary teams, including patient partners, must be involved in the design of PRO 
aspects of clinical trials to ensure that scientific, logistic, and resource considerations are addressed with 
high-quality, complete data collection in mind. Clinically informative, valid, and reliable PRO measures 
and time points for assessment should be carefully chosen to address the PRO hypotheses. A plan to 
facilitate handling of unavoidable and/or informative missing data should be employed, particularly in 
trials involving participants with advanced disease who are unlikely to complete all scheduled follow-up 
assessments. Trials should incorporate ongoing quality assurance measures. PRO findings should be 
published according to CONSORT-PRO and ISOQOL PRO reporting guidelines72,75, in a timely manner. If 
the PRO results are to be published separately, the primary trial publication should reference, or at least 
acknowledge the forthcoming PRO publication. Each trial publication should be clearly labelled with the 
trial name/number for ease of identification and to facilitate joint interpretation of PRO and other trial 
outcomes. Funders, ethics committees, journals, trial sponsors and funding bodies should proactively 
ensure PRO studies are designed, conducted, analysed and reported to these standards; this can only be 
achieved with their active engagement in such efforts. If all these stakeholders play their part, the 
outcome will be high quality PRO evidence, integrated with other trial outcomes, to better inform 
clinical decision-making and health care policy.   
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